: This study evaluates the possible effect of 9-valent (9vHPV) vaccination on the results of HPV and cytological tests in a cohort of adult women. : This study is a retrospective, single-cohort, monocentric study. Sexually active women aged 14-70 years, who underwent 9vHPV vaccination, were enrolled. Dose administration dates, side effects and data on Pap smears and HPV tests performed before and after the first vaccine dose were collected. Subjects were considered "unexposed" to the vaccine for all time intervals before the first dose administration, and "exposed" to the first, second and third vaccine doses in all time intervals following each specific dose. : A total of 512 women underwent the first 9vHPV dose administration and were enrolled in the study. Median age at vaccination was 30.5 (14-70). Log-rank tests and Cox regression analyses showed a highly statistically significant ( < 0.0001) difference in the time to negativization after the exposure to the third vaccine dose in the 207 women starting with a Pap+ smear (HR (95% C.I.), 2.66 (1.83-3.86)) and in the 198 women starting with an HPV HR+ test (HR (95% C.I.), 7.80 (4.83-12.60)). : 9vHPV vaccination may play a role in shortening the clearance time of HPV HR+ or Pap positivity in sexually active adult women.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231148 | PMC |
| http://dx.doi.org/10.3390/vaccines9060643 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Persistent infection with human papillomavirus (HPV) is associated with most cervical and anal cancer cases and a large fraction of other anogenital and oropharyngeal cancers. The prophylactic HPV vaccines are known to prevent HPV infections and HPV-associated disease, although there is evidence of reduced response to the HPV vaccination among individuals living with HIV. Prior studies among individuals without HIV suggest that a single HPV vaccine dose induces humoral immune responses that, while lower than those induced by two or three doses, still confer protection against HPV infection.
View Article and Find Full Text PDFImmunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies.
Hum Vaccin Immunother
December 2025
Merck & Co, Inc, Rahway, NJ, USA.
Post hoc analyses of 9-valent human papillomavirus (9vHPV) vaccine immunogenicity were conducted in five Phase 3 studies that enrolled males. Month 7 antibody geometric mean titers (GMTs) after three 9vHPV vaccine doses were analyzed in 10,024 males/females aged 16-26 years from studies 001 (NCT00543543), 002 (NCT00943722), 003 (NCT01651949), and 020 (NCT02114385). Covariates considered were age, gender, sexual orientation, region of residence, and race.
View Article and Find Full Text PDFHigh Prevalence of High-Risk HPV Among People with and Without HIV: Insights into Risk Factors for Tailored Screening Approaches.
Microorganisms
December 2024
Infectious Diseases Unit, Vita-Salute San Raffaele University, 20132 Milan, Italy.
Men who have sex with men (MSM) and people with HIV are at increased risk of anal HPV infection and cancer. This study aimed to assess the prevalence of anal HPV among MSM with HIV (MWH) and without HIV (MWoH), as well as among MSM under and over 35 years. Factors associated with infection from high-risk (HR) HPV were investigated.
View Article and Find Full Text PDFImpact of achieving WHO's 90-70-90 targets on cervical cancer elimination and potential benefits in preventing other HPV-related cancers in China: a modelling study.
EClinicalMedicine
November 2024
China-Australia Joint Research Centre for Infectious Diseases, School of Public Health, Xi'an Jiaotong University Health Science Centre, Xi'an, Shaanxi, China.
Background: In the context of the World Health Organization's (WHO) 90-70-90 targets for accelerating cervical cancer elimination, we aimed to assess the impact of achieving these targets and altering intervention factors on cervical cancer elimination in China and their potential benefits from preventing other human papillomavirus (HPV)-related cancers.
Methods: We developed a sexual contact network-Markov model to simulate HPV transmission and the progression of HPV-related cancers (cervical, vaginal, vulvar, penile, anal, and oropharyngeal cancers). We projected the population impact of achieving 90-70-90 targets by 2030 on the overall HPV-related cancer burden in China during 2024-2100.
Summary of the National Advisory Committee on Immunization (NACI) Statement: Updated guidance on human papillomavirus (HPV) vaccines.
Can Commun Dis Rep
December 2024
Public Health Agency of Canada, Centre for Immunization and Respiratory Infectious Diseases, Ottawa, ON.
Background: Without vaccination, approximately 75% of people in Canada will acquire a human papillomavirus (HPV) infection in their lifetime. HPV vaccine coverage rates continue to fall short of the national goal of 90% coverage for two or more doses by 17 years of age. Recent evidence and World Health Organization (WHO) guidance now support a 1- or 2-dose schedule for younger age groups, which can simplify vaccination efforts and improve coverage rates compared to a multi-dose immunization program.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!